Every 8-K that Metsera, Inc. (MTSR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MTSR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MTSR filings page.
Metsera (MTSR) completed its sale to Pfizer. At the Effective Time, each share of Metsera common stock was converted into the right to receive $65.60 in cash plus one non‑tradable contingent value right (CVR), subject to the merger terms.
The CVR pays cash only if milestones are achieved: $4.60 upon initiation of the first Phase 3 trial of the MET‑233i/MET‑097i fixed‑dose combo for chronic weight management by December 31, 2027; $9.65 upon FDA approval of that combination by December 31, 2031; and $6.40 upon FDA approval of injectable MET‑097i by December 31, 2029. CVRs carry no voting or dividend rights and are not listed or registered.
Trading of Metsera common stock ceased after market close on November 13, 2025, with delisting from Nasdaq via Form 25 and an intended Form 15 to suspend reporting. A change in control occurred as Metsera became a wholly owned Pfizer subsidiary. Directors and officers resigned per the merger agreement, with two Pfizer designees joining the board. At the special meeting, stockholders approved the merger (Votes For: 95,071,667; Against: 20,655; Abstained: 87,802), with 105,354,809 shares outstanding as of the October 24, 2025 record date.
Metsera, Inc. filed an 8-K announcing it entered into Amendment No. 1 to its Agreement and Plan of Merger with Pfizer Inc. and Mayfair Merger Sub, under which Merger Sub will merge with Metsera and Metsera will survive as a wholly owned subsidiary of Pfizer. The filing states the amendment modifies certain terms relative to the original September 21, 2025 agreement and directs readers to Exhibit 2.1 for full details.
The company also issued a press release on November 7, 2025 (Exhibit 99.1). The filing notes that completion of the proposed acquisition remains subject to customary conditions, including a stockholder vote, and includes forward‑looking statements outlining closing contingencies and related risks.
Metsera, Inc. (MTSR) filed an 8-K noting it issued a statement responding to a court ruling in litigation filed by Pfizer. The company furnished a related press release as Exhibit 99.1 dated November 5, 2025.
The disclosure reiterates forward-looking considerations tied to Pfizer’s proposed acquisition of Metsera, including risks around litigation, regulatory approvals, the required stockholder vote, and the possibility the transaction may not close. It also notes potential effects on an unsolicited proposal from Novo Nordisk A/S, as well as the possibility of competing offers. The filing emphasizes customary uncertainties related to clinical development, regulatory review, and integration if a transaction were completed.
Metsera directs investors to its definitive proxy statement and other SEC filings for details about the proposed transaction.
Metsera, Inc. (MTSR) reported that its Board determined a revised unsolicited acquisition proposal from Novo Nordisk constitutes a “Superior Company Proposal” under its existing merger agreement with Pfizer. The Novo Nordisk proposal expires at 10:00 a.m. Eastern Time on November 6, 2025. The company also received a revised proposal from Pfizer on November 3, 2025 to amend their merger agreement.
Metsera noted that Pfizer previously proposed on October 29, 2025 to increase the closing amount from $47.50 to $50.50 per share and add a term substantially similar to a provision referenced in the filing. Despite deeming Novo Nordisk’s revised bid superior under the contract definition, the Board reaffirmed its recommendation that stockholders approve the Pfizer merger on the agreed terms, and no shareholder action is required now.
Metsera also outlined expected U.S. tax treatment for a contemplated dividend, indicating it expects treatment first as a return of capital up to shareholder basis, then as capital gain, with non‑U.S. holders subject to 30% withholding pending final 2025 earnings and profits analysis.
Metsera, Inc. (MTSR) filed an 8‑K announcing it issued a statement in response to litigation filed by Pfizer. The statement is furnished as Exhibit 99.1. The filing’s forward‑looking section discusses Pfizer’s proposed acquisition of Metsera and notes risks tied to the litigation, including expenses, potential damages or other losses, and possible effects on Metsera’s business and stock price.
The disclosure also highlights conditions to closing the proposed acquisition, such as obtaining necessary regulatory approvals and the requisite stockholder vote, and acknowledges the possibility of competing offers, referencing Novo Nordisk A/S’s unsolicited proposal. Metsera has filed preliminary and definitive proxy statements related to the transaction, and the definitive proxy has been mailed to stockholders. Additional documents are available on the SEC’s website and Metsera’s site.
Metsera, Inc. filed an 8-K disclosing it issued a statement responding to litigation filed by Pfizer. The statement is furnished as Exhibit 99.1. The filing also reiterates extensive forward-looking statements tied to Pfizer’s proposed acquisition of Metsera, highlighting risks that include the litigation’s impact, regulatory approvals, the requisite stockholder vote, potential competing offers, integration uncertainties, transaction costs, market effects, and other external factors.
The company notes that a definitive proxy statement relating to the proposed transaction has been mailed to stockholders and that materials are available through the SEC and Metsera’s website. The filing clarifies it is not an offer or solicitation regarding any securities or votes.
Metsera (MTSR) announced its board has determined Novo Nordisk’s unsolicited proposal is a “Superior Company Proposal” under its existing Pfizer merger agreement. The Novo offer uses a two‑step structure: first, a Novo subsidiary would fund Metsera at $56.50 per common share, after which Metsera would declare a $56.50 per‑share cash dividend. In exchange, Metsera would issue Novo non‑voting convertible preferred stock representing 50% of fully diluted share capital on a post‑issuance basis.
In the second step, after required approvals and conditions, each common share would receive one CVR worth up to $21.25 in cash upon milestones: $4.75 for initiating the first Phase 3 of the MET‑233i/MET‑097i combo by December 31, 2027; $10.00 for U.S. FDA approval of the combo by December 31, 2031; and $6.50 for U.S. FDA approval of MET‑097i by December 31, 2029. Novo would also provide interim funding (PIK interest at 7% for certain amounts) convertible into the preferred at a $56.50 per‑share price, and pay the $190 million Pfizer termination fee upon termination of the Pfizer agreement. The Novo deal includes customary “no‑shop” and fiduciary‑out terms.
Metsera, Inc. reported positive Phase 2b results for its obesity and metabolic candidate MET-097i, a first-in-class, fully biased, ultra-long acting GLP-1 receptor agonist with potential for monthly dosing. In the VESPER-1 trial, MET-097i achieved mean placebo-subtracted weight loss of up to 14.1% after 28 weekly doses, showing substantial body-weight reduction versus placebo.
The company also reported strong tolerability from VESPER-1 and a planned interim tolerability analysis of VESPER-3. At the highest evaluated dose in VESPER-3, there was minimal diarrhea and a risk difference versus placebo of 13% for nausea and 11% for vomiting at 12 weeks after two titration steps, suggesting a potentially favorable side-effect profile for a GLP-1 therapy.
Based on these data, Metsera plans to start a global Phase 3 program for MET-097i in late 2025. Additional Phase 2b trials are underway to test a monthly dosing profile for long-term maintenance and use in people with type 2 diabetes, and MET-097i serves as the backbone for four more clinical programs in the company’s pipeline.
Metsera, Inc. disclosed a proposed merger with Pfizer Inc. under an Agreement and Plan of Merger dated September 21, 2025. The announced Merger Consideration includes a combination of cash and one contractual contingent value right (CVR) per share that may pay additional cash upon achievement of specified milestones under a CVR Agreement. Several related Voting and Support Agreements dated September 21, 2025 are filed among Pfizer, Metsera and certain ARCH and Validae investors. A Form of Letter Agreement and a Joint Press Release dated September 22, 2025 are included as exhibits. The filing notes the availability of the Company’s March 26, 2025 10-K and cautions that proxy and other documents to be filed with the SEC should be read when available for full details.